prePSMA is a randomized controlled trial in which patients with high-risk prostate cancer and selected cases with intermediate-risk disease are randomized to a control arm in which all patients undergo extended pelvic lymph node dissection (ePLND), or an experimental arm in which ePLND is only performed in patients with positive preoperative findings on prostate-specific membrane antigen positron emission tomography/computed tomography.
European urology focus. 2025 Jul 28 [Epub ahead of print]
Lars F Qvigstad, Kirsti Aas, Andreas Tulipan, Knut H Hole, Anne H Storås, Clara Hammarström, Reza Ghiasvand, Stein H Holmedal, Viktor Berge
Department of Cancer Surgery, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: ., Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Urology, Akershus University Hospital, Lørenskog, Norway., Department of Radiology and Nuclear Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Radiology, Nuclear Medicine/PET Centre, Haukeland University Hospital, Bergen, Norway., Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Radiology and Nuclear Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Department of Pathology, Akershus University Hospital, Lørenskog, Norway., Oslo Centre for Biostatistics and Epidemiology, Oslo Hospital Service, Oslo University Hospital, Oslo, Norway; Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway., Department of Radiology, Akershus University Hospital, Lørenskog, Norway., Department of Cancer Surgery, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/40731245